Raloxifene
Also known as: Evista, Ralo
Selective Estrogen Receptor Modulator | Gynecomastia & Bone Health
Overview
Raloxifene is a second-generation selective estrogen receptor modulator (SERM) FDA-approved for the prevention and treatment of postmenopausal osteoporosis and for breast cancer risk reduction. Unlike tamoxifen, raloxifene has a benzothiophene core rather than a triphenylethylene backbone, giving it a distinct tissue-selectivity profile. In performance enhancement contexts, raloxifene is widely regarded as the preferred SERM for gynecomastia reversal because of its stronger antagonist activity at breast tissue estrogen receptors with fewer off-target effects. However, raloxifene is not an effective standalone post-cycle therapy drug because it does not stimulate the hypothalamic-pituitary-testicular axis as robustly as tamoxifen or enclomiphene. Its weaker antagonism at hypothalamic estrogen receptors means it produces comparatively modest elevations in LH and FSH, making it poorly suited for driving testosterone recovery after anabolic steroid cycles. Raloxifene carries a lower risk of endometrial stimulation than tamoxifen, as it acts as an estrogen antagonist rather than a partial agonist in uterine tissue.
Key benefits
- Superior breast tissue estrogen receptor antagonism makes it the preferred SERM for gynecomastia reversal
- No estrogen agonist activity in the uterus, avoiding the endometrial risks associated with tamoxifen
- Estrogen agonist activity in bone preserves bone mineral density and reduces fracture risk
- Lower overall thromboembolic risk compared to tamoxifen
- Metabolized via glucuronidation rather than CYP2D6, avoiding the drug interaction concerns that affect tamoxifen
- Simple once-daily oral dosing with a manageable 28-hour half-life
- FDA-approved with decades of clinical safety data in postmenopausal women
Mechanism of action
Raloxifene binds to both estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta), producing tissue-dependent agonist or antagonist effects determined by the local complement of coactivator and corepressor proteins. In breast tissue, raloxifene functions as a potent estrogen antagonist, blocking estradiol-mediated proliferative signaling with high selectivity. This strong breast-tissue antagonism underlies its effectiveness for gynecomastia treatment and breast cancer risk reduction. In bone, raloxifene acts as an estrogen agonist, maintaining bone mineral density by inhibiting osteoclast-mediated resorption. Critically, raloxifene is a weaker antagonist at hypothalamic estrogen receptors compared to tamoxifen, which means it produces less disruption of estrogen-driven negative feedback on GnRH secretion. The result is a more modest increase in LH and FSH compared to tamoxifen, limiting its utility as a standalone PCT agent. In the uterus, raloxifene does not exhibit the partial agonist activity seen with tamoxifen, which translates to a substantially lower risk of endometrial hyperplasia and endometrial cancer with long-term use. Raloxifene is metabolized primarily through glucuronidation rather than CYP450-dependent oxidation, which reduces the potential for drug-drug interactions compared to tamoxifen.
Molecular data
- Type
- Benzothiophene-derived selective estrogen receptor modulator
- Half-life
- ~28 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
Gynecomastia Treatment
Bone Health
Medical (FDA-Approved)
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 60mg | Once daily for 3-6 months | — |
| — | 60mg | Once daily throughout cycle | — |
| — | 60mg | Once daily | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Hot flashes and increased sweating
- Leg cramps and muscle spasms
- Joint pain or stiffness
- Peripheral edema (mild swelling in extremities)
- Flu-like symptoms during initial weeks
Rare side effects
- Deep vein thrombosis or pulmonary embolism (lower incidence than tamoxifen but still elevated over baseline)
- Retinal vein thrombosis or other visual disturbances
- Stroke (risk elevated primarily in women with pre-existing cardiovascular risk factors)
- Elevated triglycerides in individuals with pre-existing hypertriglyceridemia
- Hepatic dysfunction or elevated liver enzymes
Contraindications
- History of deep vein thrombosis, pulmonary embolism, retinal vein thrombosis, or other venous thromboembolic events
- Active or past history of stroke or transient ischemic attack
- Known hypersensitivity to raloxifene hydrochloride or any excipients
- Pregnancy or planned pregnancy (category X -- contraindicated)
- Prolonged immobilization (e.g., post-surgical recovery, extended bed rest) due to elevated DVT risk
- Severe hepatic impairment
References
Primary literature and clinical-trial data informing this entry.